Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Claire on +441494 818 025 or claire@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Claire Roberts
Director
claire@zenopa.com
+441494 818 025

Testimonials
I want to take this opportunity to say “thank you” very much for all your help and support with my job searching. The professionalism that Zenopa showed me was also brilliant.
Suraj , 2014

Lilly agrees Avid Radiopharmaceuticals takeover

9 November 2010 00:00 in Pharmaceutical Company Restructures


Lilly has agreed to acquire the privately-held healthcare firm Avid Radiopharmaceuticals in a transaction worth up to $800 million (495.7 million pounds).

The pharmaceutical company is to pay an upfront fee of $300 million for all outstanding Avid shares and will be eligible for up to $500 million in additional payments, based on the future commercial and regulatory progress of Avid products.

In acquiring the firm, Lilly takes control of a portfolio of products for the detection and monitoring of chronic conditions, including Parkinson's disease and diabetes.

Avid's lead development programme is florbetapir, a promising molecular imaging agent which can help to detect amyloid plaque in the brain to help diagnose Alzheimer's disease.

Dr John Lechleiter, Lilly's chairman and chief executive officer, said: "The acquisition of Avid Radiopharmaceuticals aligns well with Lilly's innovation-based strategy, offers a potential near-term revenue opportunity, leverages our neuroscience expertise and will immediately bolster our diagnostics capabilities."

Last month, Lilly published its financial report for the third quarter of 2010, noting a two percent year-over-year revenue growth.ADNFCR-8000103-ID-800224533-ADNFCR

Other news stories from 09/11/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd